Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05392075 · ClinicalTrials.gov registry record
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 100
- Enrollment target
NCT05392075: Completed study, sponsored by Methodist Health System.
NCT05392075 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05392075 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus \[2019-nCoV\]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019. The virus quickly spread to other countries and on March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. By March 2021, many nations and organizations embarked on finding a cure or vaccine for this devastating viral infection. The Pfizer COVID-19 mRNA vaccine was the first to obtain emergency use authorization (EUA) from the Food \& Drug Administration (FDA) on December 11, 2020, followed by the Moderna COVID-19 mRNA vaccine on December 18, 2020, and the Janssen COVID-19 viral vector vaccine on February 27, 2021. The mRNA vaccines and the viral vector vaccine are designed based on the spike protein of SARS-COV-2. These vaccines had been administered to millions of Americans prior to July 2021.
Primary Outcome
The number of COVID-19 breakthrough infections in fully vaccinated participants
Interventions
- BIOLOGICAL Pfizer COVID-19 mRNA vaccine
- BIOLOGICAL Moderna COVID-19 mRNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-08-17 |
What the finished NCT05392075 record still lists
NCT05392075 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Pfizer COVID-19 mRNA vaccine is the first listed.
NCT05392075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05392075 about?
NCT05392075 is a clinical study titled "COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose". A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus \[2019-nCoV\]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019. The virus quickly spread to other countries and on March 11, 2020, the World Health Organi...
What is the current status of trial NCT05392075?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2023-03-15. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT05392075?
The interventions under investigation include: Pfizer COVID-19 mRNA vaccine (BIOLOGICAL), Moderna COVID-19 mRNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05392075?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI